BLK抗体

+ +

•  

   

     Immunofluorescence analysis of Hela cells using BLK mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using BLK mouse mAb (green) and negative control (purple).    

  
  

BLK (B lymphocyte kinase) is a non-receptor tyrosine kinase belonging to the Src family, primarily expressed in B cells and involved in B-cell receptor (BCR) signaling. It plays a critical role in regulating B-cell development, activation, and differentiation by mediating intracellular signaling cascades. Dysregulation of BLK has been implicated in autoimmune diseases, particularly systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), where genetic variants near the BLK locus are associated with increased disease risk. Studies suggest that altered BLK activity may disrupt immune tolerance, leading to aberrant B-cell responses and autoantibody production.

Antibodies targeting BLK are essential tools for studying its function and disease mechanisms. They are used in research to detect BLK expression levels, investigate its interaction with signaling molecules (e.g., Syk, PI3K), and assess phosphorylation events critical for B-cell activation. In clinical contexts, anti-BLK antibodies may aid in diagnosing autoimmune conditions or stratifying patients based on BLK-related genetic markers. Additionally, therapeutic strategies exploring BLK inhibition are under investigation to modulate overactive B-cell signaling in autoimmune disorders. However, the dual role of BLK in both physiological immunity and pathology requires careful balancing to avoid immunosuppressive side effects. Ongoing research aims to clarify its precise mechanisms and therapeutic potential.